Ramy Ibrahim

8.4k total citations
66 papers, 2.4k citations indexed

About

Ramy Ibrahim is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ramy Ibrahim has authored 66 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 24 papers in Immunology and 16 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ramy Ibrahim's work include Cancer Immunotherapy and Biomarkers (33 papers), CAR-T cell therapy research (18 papers) and Immunotherapy and Immune Responses (15 papers). Ramy Ibrahim is often cited by papers focused on Cancer Immunotherapy and Biomarkers (33 papers), CAR-T cell therapy research (18 papers) and Immunotherapy and Immune Responses (15 papers). Ramy Ibrahim collaborates with scholars based in United States, Italy and Belgium. Ramy Ibrahim's co-authors include Axel Hoos, Rachel Humphrey, Michele Maio, Hubert Pehamberger, Steven O’Day, J. D. Wolchok, Jedd D. Wolchok, Samir N. Khleif, Veerle de Pril and Sylvia Janetzki and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ramy Ibrahim

61 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ramy Ibrahim United States 24 2.0k 1.2k 462 430 151 66 2.4k
Theresa M. Salay United States 6 2.1k 1.1× 1.3k 1.2× 578 1.3× 484 1.1× 112 0.7× 6 2.7k
Ruggero Ridolfi Italy 25 1.9k 0.9× 1.1k 1.0× 408 0.9× 774 1.8× 135 0.9× 97 2.4k
Elizabeth Stankevich United States 15 2.4k 1.2× 1.3k 1.1× 665 1.4× 416 1.0× 337 2.2× 39 2.9k
Julian A. Marin‐Acevedo United States 13 1.1k 0.6× 732 0.6× 358 0.8× 354 0.8× 106 0.7× 27 1.7k
Oliver Bohnsack United States 5 2.0k 1.0× 957 0.8× 700 1.5× 386 0.9× 70 0.5× 12 2.4k
Periklis Foukas Greece 21 1.2k 0.6× 970 0.8× 261 0.6× 447 1.0× 143 0.9× 76 2.2k
Sana Intidhar Labidi‐Galy Switzerland 23 1.6k 0.8× 924 0.8× 358 0.8× 410 1.0× 99 0.7× 55 2.4k
Emilia Cocorocchio Italy 19 1.2k 0.6× 481 0.4× 320 0.7× 456 1.1× 107 0.7× 65 1.8k
Kristen A. Marrone United States 16 1.5k 0.7× 418 0.4× 761 1.6× 458 1.1× 123 0.8× 74 2.0k
Philip D. Leming United States 14 1.5k 0.8× 608 0.5× 580 1.3× 471 1.1× 71 0.5× 21 1.9k

Countries citing papers authored by Ramy Ibrahim

Since Specialization
Citations

This map shows the geographic impact of Ramy Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramy Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramy Ibrahim more than expected).

Fields of papers citing papers by Ramy Ibrahim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramy Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramy Ibrahim. The network helps show where Ramy Ibrahim may publish in the future.

Co-authorship network of co-authors of Ramy Ibrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Ramy Ibrahim. A scholar is included among the top collaborators of Ramy Ibrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ramy Ibrahim. Ramy Ibrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Subudhi, Sumit K., Wim Vos, Massimo Andreatta, et al.. (2025). Perspectives on the role of “-Omics” in predicting response to immunotherapy. European Journal of Cancer. 220. 115393–115393. 2 indexed citations
2.
Ibrahim, Ramy, et al.. (2025). Diabetic Distress among Patients with Type II: A Descriptive Study. Advanced Biomedical Research. 14(1). 23–23. 1 indexed citations
3.
Ibrahim, Ramy, et al.. (2024). A Case Report on Iatrogenic Methotrexate Toxicity. Cureus. 16(7). e64081–e64081.
4.
Giacomo, Anna Maria Di, Michael Lahn, Alexander M.M. Eggermont, et al.. (2023). The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?. European Journal of Cancer. 198. 113501–113501. 5 indexed citations
5.
Friedman, Claire F., Christine N. Spencer, Christopher R. Cabanski, et al.. (2022). Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Journal for ImmunoTherapy of Cancer. 10(1). e003853–e003853. 30 indexed citations
6.
Mair, Maximilian J., Michele Ceccarelli, Andrea Anichini, et al.. (2022). Immunotherapy for brain metastases and primary brain tumors. European Journal of Cancer. 179. 113–120. 13 indexed citations
7.
Maio, Michele, Christian U. Blank, Andrea Necchi, et al.. (2021). Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. European Journal of Cancer. 152. 155–164. 23 indexed citations
8.
Stewart, Mark, Lisa H. Butterfield, Bruce L. Levine, et al.. (2020). Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy. 22(5). 239–246. 7 indexed citations
9.
Ibrahim, Ramy, et al.. (2018). Pulmonary embolism secondary to uterine fibroid: A case report of a rare presentation. 11(1). 3 indexed citations
10.
Maio, Michele, George Coukos, Soldano Ferrone, et al.. (2018). Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. Cancer Immunology Immunotherapy. 68(1). 1–9. 8 indexed citations
11.
Giacomo, Anna Maria Di, et al.. (2018). The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology. Cancer Immunology Immunotherapy. 68(1). 143–150.
12.
Ibrahim, Ramy, et al.. (2017). Paget-Schroetter syndrome in the absence of common predisposing factors: a case report. Thrombosis Journal. 15(1). 20–20. 8 indexed citations
13.
Calabrò, Luana, Giovanni Luca Ceresoli, Alessandra di Pietro, et al.. (2014). CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. Cancer Immunology Immunotherapy. 64(1). 105–112. 16 indexed citations
14.
Forero, Andres, Mehdi Hamadani, Thomas J. Kipps, et al.. (2013). Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab. Journal for ImmunoTherapy of Cancer. 1(S1). 3 indexed citations
15.
Rahma, Osama E., Ramy Ibrahim, Antoun Toubaji, et al.. (2010). A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. Journal of Translational Medicine. 8(1). 8–8. 25 indexed citations
16.
Hoos, Axel, Ramy Ibrahim, Alan J. Korman, et al.. (2010). Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy. Seminars in Oncology. 37(5). 533–546. 196 indexed citations
17.
Harmankaya, Kaan, Claus Koelblinger, Ramy Ibrahim, et al.. (2010). Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Medical Oncology. 28(4). 1140–1144. 83 indexed citations
18.
Davis, Keith L., Debanjali Mitra, Srividya Kotapati, Ramy Ibrahim, & Jedd D. Wolchok. (2009). Direct economic burden of high-risk and metastatic melanoma in the elderly. Applied Health Economics and Health Policy. 7(1). 31–41. 21 indexed citations
19.
Wolchok, Jedd D., Veerle de Pril, Gerald P. Linette, et al.. (2009). Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors. Journal of Clinical Oncology. 27(15_suppl). 9036–9036. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theresa M. Salay Breakdown of academic impact, for papers by Ruggero Ridolfi Breakdown of academic impact, for papers by Elizabeth Stankevich Breakdown of academic impact, for papers by Julian A. Marin‐Acevedo Breakdown of academic impact, for papers by Oliver Bohnsack Breakdown of academic impact, for papers by Periklis Foukas Breakdown of academic impact, for papers by Sana Intidhar Labidi‐Galy Breakdown of academic impact, for papers by Emilia Cocorocchio Breakdown of academic impact, for papers by Kristen A. Marrone Breakdown of academic impact, for papers by Philip D. Leming
Rankless by CCL
2026